GlassScriptPhysician profile
Ada Lopez-Mendez
NPI 1841267143
$994.60
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $87.15 · 2021: $206 · 2022: $282.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $216.94 | 2019 | |
| Amgen INC. | $176.22 | 2019-2021 | |
| Glaxosmithkline, LLC. | $132.44 | 2022 | |
| Aurinia Pharma U.S., INC. | $125.05 | 2022 | |
| Janssen Scientific Affairs, LLC | $115.53 | 2021 | |
| Pfizer INC. | $100.52 | 2019-2020 | |
| Abbvie INC. | $67.98 | 2020-2022 | |
| Ucb, INC. | $26.19 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $22.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.34 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ada Lopez-Mendez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.